Cyclophosphamide

證據等級: L5

預測適應症: 5 個

Cyclophosphamide: From Alkylating Chemotherapy to Myeloid Leukemia

One-Sentence Summary

Cyclophosphamide is a well-established nitrogen mustard alkylating agent used globally in oncology and immunosuppression, though it currently holds no registered indication in the Philippines. The TxGNN model predicts it may be effective for Myeloid Leukemia, with multiple Phase 2/3 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	No Philippines registration; globally used as alkylating chemotherapy for cancers and autoimmune conditions
Predicted New Indication	Myeloid Leukemia
TxGNN Prediction Score	99.47%
Evidence Level	L1
Philippines Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack (listed as a high-severity data gap). Based on established pharmacology, Cyclophosphamide is a nitrogen mustard alkylating agent that works by crosslinking DNA strands — both inter-strand and intra-strand — thereby blocking DNA replication and triggering apoptosis in rapidly dividing cells. This mechanism is particularly effective against high-proliferation malignancies such as leukemia, where tumor cells divide continuously.

Cyclophosphamide plays a central role in myeloid leukemia treatment through two mechanistically distinct strategies. First, as a myeloablative conditioning agent prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is combined with busulfan (BuCy regimen) or total-body irradiation (TBI/Cy) to eradicate residual leukemia and permit donor engraftment — this is a globally accepted standard approach for AML patients proceeding to transplant. Second, as post-transplant cyclophosphamide (PTCy), administered on Day +3 and +4 after transplantation, it has emerged as a highly effective and widely adopted GvHD prophylaxis strategy, particularly in haploidentical HSCT settings, demonstrating favorable relapse-free survival outcomes in both adult and pediatric AML cohorts.

The TxGNN model’s high-confidence prediction of 99.47% reflects this robust, multi-faceted linkage between cyclophosphamide’s known biology and its established clinical role across the myeloid leukemia treatment spectrum. The drug’s dual capacity — direct leukemia cell kill at high doses and immune modulation at lower doses — provides a compelling mechanistic foundation for continued and expanded application in myeloid leukemia.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06098313	Phase 2	Active, not recruiting	113	Evaluates post-transplant cyclophosphamide (PTCy) with myeloablative or reduced-intensity conditioning for allo-HCT in higher-risk MDS and secondary AML; primary endpoint is GvHD-free, relapse-free survival
NCT07132684	Phase 3	Recruiting	240	Multicenter randomized comparison of Venetoclax+Azacitidine (VA) vs Daunorubicin/Idarubicin+Cytarabine (D/IA) as induction regimens in elderly (ages 55–75) AML patients fit for intensive chemotherapy
NCT00002798	Phase 3	Completed	880	Landmark randomized trial comparing multiple chemotherapy regimens with or without bone marrow transplantation in children with untreated AML or MDS
NCT00002945	Phase 3	Completed	61	High-dose cytarabine+idarubicin induction followed by high-dose etoposide+cyclophosphamide intensification, ASCT, and IL-2 immunomodulation for previously untreated de novo and secondary adult myeloid leukemia
NCT00005898	Phase 1/2	Completed	30	TBI + Cyclophosphamide + Fludarabine + ATG conditioning followed by HLA non-identical T-cell depleted HCT; assessed engraftment probability and GvHD incidence in AML/Fanconi’s anemia
NCT00134004	Phase 2	Completed	210	Fludarabine + cyclophosphamide-based non-myeloablative conditioning followed by partially HLA-mismatched bone marrow transplantation for hematologic malignancies including AML
NCT01370213	Phase 2	Completed	25	NK cell-based non-myeloablative haploidentical transplantation for high-risk acute myeloid diseases; cyclophosphamide as part of conditioning; assessed leukemia-free neutrophil engraftment at Day +28
NCT03417154	Phase 2	Completed	12	Nivolumab + low-dose oral cyclophosphamide combination for relapsed/refractory AML and higher-risk MDS in patients not eligible for or declining HSCT; included randomized pilot sub-study
NCT06802315	Phase 2	Recruiting	38	Intensity-modulated total marrow irradiation (IM-TMI, 9 Gy) + Fludarabine/Busulfan (FluBu4) + post-transplant cyclophosphamide (Day +3/+4) for high-risk AML, CML, and MDS allo-HSCT
NCT01010217	Phase 2	Completed	176	Three-arm study comparing haploidentical, 1-antigen mismatched, and matched unrelated donor transplantation using T-cell replete allograft with high-dose post-transplant cyclophosphamide for hematologic malignancies

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40434956	2025	RCT	Future Oncology	Compares BuCy vs FluBu myeloablative conditioning for allo-HSCT in AML; FluBu shows similar efficacy with potentially lower toxicity profile
35955881	2022	Prospective	Int J Mol Sci	PTCy after matched sibling and unrelated donor HSCT in pediatric AML; improved GvHD and relapse-free survival, supporting PTCy beyond haploidentical settings
38499049	2024	Prospective Phase 2	Transplant Immunology	Cladribine + BuCy as intensive conditioning prior to allo-HSCT for relapsed/refractory AML; demonstrated feasibility and preliminary efficacy
25345651	2015	Prospective Phase 2	Am J Hematol	Cy/Flu non-myeloablative allotransplant vs myeloablative allotransplant for 165 AML patients in remission; comparable event-free and overall survival at median 61-month follow-up
39939431	2025	Retrospective Cohort	Bone Marrow Transplantation	EBMT registry analysis of 1,823 AML patients in CR1 receiving PTCy-based HSCT; myeloablative conditioning superior in adverse-risk cytogenetics
40437709	2025	Retrospective Cohort	Eur J Haematol	RIC vs MAC conditioning in AML (<65 years) with ATG + PTCy + cyclosporine prophylaxis; MAC associated with lower relapse risk
38466265	2024	Retrospective Cohort	Cytotherapy	Prognostic factors in haploidentical HSCT with PTCy for AML; PTCy provides effective GvHD suppression; disease status at transplant is the dominant prognostic factor
40905088	2026	Retrospective Cohort	Haematologica	217 AML patients in CR receiving MAC allo-HCT + PTCy-based GvHD prophylaxis; 2-year OS 77%, EFS 72%; adverse-risk patients had significantly worse outcomes
33325761	2021	Retrospective Case Series	Leukemia & Lymphoma	High-dose cyclophosphamide (60 mg/kg) for cytoreduction in AML with hyperleukocytosis or leukostasis (WBC ≥50×10⁹/L); 41% response rate with acceptable safety
29039989	2017	Case Series	Pediatr Hematol Oncol	Clofarabine + cyclophosphamide + etoposide for relapsed/refractory childhood and adolescent AML (n=17); 41% overall response rate (4 CR, 1 CRi, 2 PR)

Philippines Market Information

Cyclophosphamide currently has no registered product authorizations in the Philippines. The drug is classified as Not Marketed, with zero product licenses on record in the Philippines FDA database. Any clinical use would require evaluation through the Philippines FDA’s compassionate special permit or importation pathway for unregistered drugs.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Nitrogen mustard alkylating agent
Myelosuppression Risk	High — Neutropenia, thrombocytopenia, and anemia are dose-limiting toxicities; nadir typically occurs 10–14 days after administration
Emetogenicity Classification	Moderate to High — Dose-dependent; single doses >1,500 mg/m² are highly emetogenic; standard doses are moderately emetogenic
Monitoring Items	CBC with differential (at least weekly during treatment), liver function tests, renal function (serum creatinine, BUN), urinalysis and urine dipstick for hematuria (hemorrhagic cystitis monitoring)
Handling Protection	Must follow cytotoxic drug handling regulations; high-dose regimens (≥1,000 mg/m²) require co-administration of mesna and aggressive IV hydration to prevent hemorrhagic cystitis

Safety Considerations

Please refer to the package insert for safety information.

Important: Key warnings, contraindications, and drug interaction data were identified as blocking and high-severity data gaps in this evidence pack. Based on established pharmacology, critical known risks include: hemorrhagic cystitis (requiring mesna and hydration at high doses), severe myelosuppression (infection and bleeding risk), secondary malignancies (therapy-related AML with long-term use), and gonadotoxicity (infertility risk, particularly in young patients). A formal safety review using the complete product package insert is required before any clinical decision.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence supporting cyclophosphamide in myeloid leukemia is exceptionally strong (Evidence Level L1), with multiple completed Phase 3 trials — including an 880-patient landmark pediatric AML trial (NCT00002798) — and extensive Phase 2 evidence across HSCT conditioning (BuCy), post-transplant GvHD prophylaxis (PTCy), and direct cytoreduction settings. The TxGNN prediction score of 99.47% accurately reflects this well-established, mechanistically coherent evidence base. However, the drug is currently unregistered in the Philippines and critical safety documentation is absent from the evidence pack, warranting guardrails before any clinical pathway is initiated.

To proceed, the following is needed:

Safety documentation (Blocking): Download and analyze the complete package insert/SmPC to document key warnings, contraindications, and drug-drug interactions — currently a blocking data gap that prevents safety pre-screening
Philippines regulatory pathway: Evaluate the Philippines FDA compassionate special permit or importation pathway for an unregistered drug; confirm availability of mesna for hemorrhagic cystitis prevention
MOA documentation (High priority): Obtain formal mechanism of action data from the DrugBank API to complete the mechanistic linkage analysis
Patient population definition: Specify the target AML subgroup (de novo vs. secondary AML; age bracket; cytogenetic/molecular risk category: favorable, intermediate, or adverse) to align with the appropriate evidence base
Institutional capacity assessment: Confirm availability of HSCT infrastructure, supportive care (G-CSF, blood products, antimicrobial prophylaxis), and therapeutic drug monitoring for busulfan if BuCy conditioning is considered
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.